Edith Bonnelye

4.7k total citations · 2 hit papers
58 papers, 3.8k citations indexed

About

Edith Bonnelye is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Edith Bonnelye has authored 58 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 27 papers in Oncology and 19 papers in Genetics. Recurrent topics in Edith Bonnelye's work include Bone Metabolism and Diseases (22 papers), Bone health and treatments (18 papers) and Estrogen and related hormone effects (18 papers). Edith Bonnelye is often cited by papers focused on Bone Metabolism and Diseases (22 papers), Bone health and treatments (18 papers) and Estrogen and related hormone effects (18 papers). Edith Bonnelye collaborates with scholars based in France, Canada and United States. Edith Bonnelye's co-authors include Jane E. Aubin, Pierre Jurdic, Frédéric Saltel, Anne Chabadel, Philippe Clézardin, Vincent Laudet, Céline Le Gall, Jonathan Green, Xavier Desbiens and Ingunn Holen and has published in prestigious journals such as Journal of Biological Chemistry, Physiological Reviews and The Journal of Cell Biology.

In The Last Decade

Edith Bonnelye

55 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro

2007 676 citations Edith Bonnelye, Frédéric Saltel et al. profile →
Bone metastasis: mechanisms, therapies, and biomarkers

2020 243 citations Philippe Clézardin, Edith Bonnelye et al. profile →

Peers

Countries citing papers authored by Edith Bonnelye

Since Specialization

Citations

This map shows the geographic impact of Edith Bonnelye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edith Bonnelye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edith Bonnelye more than expected).

Fields of papers citing papers by Edith Bonnelye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edith Bonnelye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edith Bonnelye. The network helps show where Edith Bonnelye may publish in the future.

Co-authorship network of co-authors of Edith Bonnelye

This figure shows the co-authorship network connecting the top 25 collaborators of Edith Bonnelye. A scholar is included among the top collaborators of Edith Bonnelye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edith Bonnelye. Edith Bonnelye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bone Effects of Anti-Cancer Treatments in 2024 2025 ·Calcified Tissue International ·(unknown), (unknown), Emmanuel Biver, Peyman Hadji, Edith Bonnelye, Peter R. Ebeling, David L. Kendler, (unknown), Gerold Holzer, Jean‐Jacques Body, Ghada El‐Hajj Fuleihan, Maria Luisa Brandi, René Rizzoli, Cyrille B. Confavreux	0
2	Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases 2024 ·Journal of bone oncology ·(unknown), (unknown), Julien Péron, Denis Maillet, Stéphane Dalle, (unknown), Emmanuel Grolleau, Philippe Clézardin, Edith Bonnelye, Christian Confavreux, (unknown)	1
3	Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions 2021 ·Oncogene ·Francesco Pantano, Martine Croset, Keltouma Driouch, Natalia Bednarz‐Knoll, Michele Iuliani, Giulia Ribelli, Edith Bonnelye, Harriet Wikman, (unknown), Florian Bonin, Sonia Simonetti, Bruno Vincenzi, Saw See Hong, Sofia Sousa, Klaus Pantel, Giuseppe Tonini, Daniele Santini, Philippe Clézardin	69
4	Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma 2021 ·Journal of bone oncology ·(unknown), (unknown), (unknown), Edith Bonnelye, Marie Brevet, (unknown), M. Duruisseaux, Olivier Borel, (unknown), (unknown), Jean‐Baptiste Pialat, Évelyne Gineyts, (unknown), (unknown), (unknown), Philippe Clézardin, Nicolas Girard, Cyrille B. Confavreux	7
5	ERRα Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response 2020 ·Cancer Research ·(unknown), Alexandra Lainé, Cyril Boyault, (unknown), Emmanuelle Meugnier, (unknown), Casina W.S. Kan, (unknown), (unknown), Héctor Hernández‐Vargas, Claire Benetollo, Yuji Yoshiko, Martine Duterque‐Coquillaud, Philippe Clézardin, Julien C. Marie, Edith Bonnelye	22
6	miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis–Associated Genes 2018 ·Cancer Research ·Martine Croset, Francesco Pantano, Casina W.S. Kan, Edith Bonnelye, Françoise Descôtes, Catherine Alix‐Panabières, Charles‐Henri Lecellier, Richard Bachelier, Nathalie Allioli, Saw-See Hong, Kai Bartkowiak, Klaus Pantel, Philippe Clézardin	150
7	The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis 2018 ·Calcified Tissue International ·Évelyne Gineyts, Nicolas Bonnet, C. Bertholon, (unknown), (unknown), Olivier Borel, (unknown), Edith Bonnelye, Martine Croset, (unknown), Cristina I. Truica, (unknown), Kim Leitzel, Daniel Hartmann, Roland Chapurlat, Allan Lipton, Patrick Garnero, Serge Ferrari, Philippe Clézardin, Jean‐Charles Rousseau	9
8	Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone 2016 ·Cancer Research ·Caroline Reynaud, (unknown), Paola Di Mauro, Casina W.S. Kan, Martine Croset, Edith Bonnelye, Floriane Pez, Clémence Thomas, (unknown), Antoine E. Karnoub, Marie Brevet, Philippe Clézardin	56
9	Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Short Title: LOX triggers tumor cell colonization in bone 2016 ·Cancer Research ·Caroline Reynaud, (unknown), Paola Di Mauro, Casina W.S. Kan, Martine Croset, Edith Bonnelye, Floriane Pez, Clémence Thomas, (unknown), Antoine E. Karnoub, Marie Brevet, Philippe Clézardin	1
10	In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement 2012 ·Clinical Cancer Research ·Ismahène Benzaïd, Hannu Mönkkönen, Edith Bonnelye, Jukka Mönkkönen, Philippe Clézardin	43
11	Dual Function of ERRα in Breast Cancer and Bone Metastasis Formation: Implication of VEGF and Osteoprotegerin 2011 ·Cancer Research ·(unknown), (unknown), (unknown), Delphine Goehrig, Baptiste Dépalle, Akeila Bellahcène, (unknown), Hélène Follet, Françoise Descôtes, Jane E. Aubin, Philippe Clézardin, Edith Bonnelye	69
12	High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote Vγ9Vδ2 T-Cell Chemotaxis and Cytotoxicity In Vivo 2011 ·Cancer Research ·Ismahène Benzaïd, Hannu Mönkkönen, Verena Stresing, Edith Bonnelye, Jonathan Green, Jukka Mönkkönen, Jean‐Louis Touraine, Philippe Clézardin	124
13	Estrogen receptor–related receptor α regulation by interleukin‐1β in prostaglandin E₂– and cAMP‐dependent pathways in osteoarthritic chondrocytes 2011 ·Arthritis & Rheumatism ·Edith Bonnelye, Pascal Reboul, Nicolas Duval, (unknown), Jane E. Aubin	26
14	Estrogen receptor-related receptor- (ERR- ) is dysregulated in inflammatory arthritis 2008 ·Lara D. Veeken ·Edith Bonnelye, Nancy Laurin, Pierre Jurdic, David A. Hart, Jane E. Aubin	20
15	Expression and function of semaphorin 7A in bone cells 2005 ·Biology of the Cell ·(unknown), Frédéric Saltel, Edith Bonnelye, Pierre Jurdic, Irma Machuca‐Gayet	79
16	Structural and functional divergence of a nuclear receptor of the RXR family from the trematode parasite Schistosoma mansoni 2000 ·HAL (Le Centre pour la Communication Scientifique Directe) ·(unknown), Héctor Escrivá, Didier Bouton, (unknown), Jean-Marc Vanacker, Edith Bonnelye, J. Cornette, (unknown), Vincent Laudet	1
17	Structural and functional divergence of a nuclear receptor of the RXR family from the trematode parasite Schistosoma mansoni 2000 ·European Journal of Biochemistry ·(unknown), Héctor Escrivá, Didier Bouton, Dominique Zelus, Jean‐Marc Vanacker, Edith Bonnelye, J. Cornette, Raymond J. Pierce, Vincent Laudet	33
18	Osteoprotegerin and its Ligand: A New Paradigm for Regulation of Osteoclastogenesis and Bone Resorption 2000 ·Osteoporosis International ·Jane E. Aubin, Edith Bonnelye	242
19	Activation of the thyroid hormone receptor α gene promoter by the orphan nuclear receptor ERRα 1998 ·Oncogene ·Jean‐Marc Vanacker, Edith Bonnelye, (unknown), Vincent Laudet	63
20	The ERR-1 Orphan Receptor Is a Transcriptional Activator Expressed During Bone Development 1997 ·Molecular Endocrinology ·Edith Bonnelye, (unknown), (unknown), Agnès Bégué, Xavier Desbiens, David T. Denhardt, Jane E. Aubin, (unknown), Brigitte Fournier	129

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact